Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15664970 | 0.96 | PTGS2 (0.42) | PTGS2TNIKMAP4K4MAPK9CSNK1A1 | |
| SCHEMBL27934206 | 0.83 | PHF8 (0.50) | PTGS2KDM4CTGFBR1L3MBTL1PDGFRB | |
| SCHEMBL28089176 | 0.81 | PTGS2 (0.41) | PTGS2L3MBTL1PDGFRBPDGFRAPTGS1 | |
| SCHEMBL27934237 | 0.79 | PTGS2 (0.43) | PTGS2NR3C2KDM4CTGFBR1MAPT | |
| SCHEMBL15664969 | 0.79 | PDGFRB (0.39) | PTGS2TNIKMAPTL3MBTL1PDGFRB | |
| SCHEMBL28805345 | 0.77 | SMN1; SMN2 (0.42) | PTGS2NR3C2MAPTL3MBTL1MAPK13 | |
| SCHEMBL28089178 | 0.76 | ALDH1A1 (0.40) | PTGS2L3MBTL1PDGFRBPDGFRAPTGS1 | |
| SCHEMBL28089068 | 0.76 | PTGS2 (0.43) | PTGS2MAPTL3MBTL1PDGFRBPDGFRA | |
| SCHEMBL15664996 | 0.76 | PTGS2 (0.47) | PTGS2L3MBTL1PDGFRBPDGFRAPTGS1 | |
| SCHEMBL27934317 | 0.73 | PTGS2 (0.55) | PTGS2KDM4CTGFBR1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2730565-B1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2017-04-26 | — | — | EP | claimed |
| US-9139574-B2 | Tumor targeted drug combretastatin A4 derivative | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2015-09-22 | — | — | US | claimed |
| EP-2730565-A1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2014-05-14 | — | — | EP | claimed |
| US-20140128384-A1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2014-05-08 | — | — | US | claimed |
| EP-2730565-B1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2017-04-26 | — | — | EP | disclosed |
| US-9139574-B2 | Tumor targeted drug combretastatin A4 derivative | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2015-09-22 | — | — | US | disclosed |
| EP-2730565-A1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2014-05-14 | — | — | EP | disclosed |
| US-20140128384-A1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2014-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128384-A1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | TUBA4A, TUBGCP4, TUBB4A | PTGS2 4150/4885TNIK 1282/4885MAP4K4 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.